Recent Updates
Recently added Catalysts
VSTM Positive Sentiment

Verastem Oncology Announces Late-Breaking Oral Presentation of VS-7375 Lung Cancer Data at IASLC/ASCO 2026 North America Conference on Lung Cancer

Key Takeaway: Verastem Oncology announced that updated clinical data from the Phase 1/2 TARGET-D-101 study of VS-7375 will be presented at the IASLC/ASCO 2026 North America Conference. The study focuses on patients with KRAS G12D-mutated metastatic non-small cell lung cancer. This late-breaking abstract highlights the company's commitment to advancing treatments for RAS/MAPK pathway-driven cancers.

Market Sentiment Analysis

POSITIVE FACTORS

  • Late-breaking abstract selected for oral presentation.
  • Updated clinical data from Phase 1/2 study.
  • Focus on KRAS G12D-mutated metastatic NSCLC.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+193%
120-day peak, hindsight
Typical move
9.4%
average across 10 past catalysts
Cash runway
~15 mo
Medium dilution risk
Lead asset
VS-7375
Phase 2 · Pancreatic Ductal Adenocarcinoma

Full Press Release Details

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that a late-breaking abstract featuring updated clinical data from the Phase 1/2 TARGET-D-101 study of VS-7375 in previously treated patients with KRAS G12D-mutated metastatic non-small cell lung cancer (NSCLC) has been selected for oral presentation at the IASLC/ASCO 2026 North America Conference on Lung C

Frequently Asked Questions

What is the TARGET-D-101 study?

The TARGET-D-101 study evaluates VS-7375 in KRAS G12D-mutated lung cancer.

Where will the data be presented?

The data will be presented at the IASLC/ASCO 2026 North America Conference.

What type of cancer is VS-7375 targeting?

VS-7375 targets KRAS G12D-mutated metastatic non-small cell lung cancer.

What phase is the TARGET-D-101 study?

The TARGET-D-101 study is a Phase 1/2 clinical trial.

Last updated: Nov 18, 2026